Networks of Centres of Excellence of Canada
Government of Canada

Common menu bar links

Centre for Commercialization of Regenerative Medicine - CCRM

$15 million for 2011-17
About   |   News   |   Features   |   Videos
Centre for Commercialization of Regenerative Medicine

Number of partners
34

Partner contributions
$10 million

Headquarters
Toronto, Ontario

President and CEO
Michael May Michael May

Chief Scientific Officer
Peter Zandstra Peter Zandstra

Board chair
Gregory Bonfiglio Gregory Bonfiglio,
Founder and Managing Partner, Proteus Venture Partners

Turning the promise of regenerative medicine into reality


The opportunity

Regenerative medicine (RM)-based therapies hold enormous potential to repair, regenerate or replace diseased cells, tissues and organs. But many of these potentially life-changing treatments never reach patients because they are not successfully moved from the lab to the clinic. Fortunately, Canada is a global hotbed for stem cell research, bioengineering and biomaterials. Building on this expertise, stem cell scientists and bioengineers across six RM centres in Ontario supported the creation of a new commercialization centre that would bridge the gap between academia and industry and enable promising technologies to reach the market. By integrating Canada’s strength in stem cell and biomaterials sciences with dynamic business leadership and the formation of an industry consortium of nearly 40 companies, CCRM is becoming a global nexus of RM commercialization.

How CCRM is seizing the opportunity

The Centre for Commercialization of Regenerative Medicine overcomes two major bottlenecks in RM commercialization: a dearth of early stage capital and access to centralized research infrastructure. CCRM provides small- and medium-sized enterprises, large multinationals and emerging biotechnology companies with a single entry point for accessing Canada-wide RM expertise and infrastructure. CCRM’s industry consortium of nearly 40 Canadian and international RM companies can also access a fully resourced, 550 sq metre development facility designed for bioprocess optimization. CCRM is capitalizing on its extensive pipeline of ideas to bundle promising technologies into 10 new companies that are strategic and leverage expertise, funding and excellent science.

Among the results

  • A 1850 sq metre state-of-the-art GMP (good manufacturing practice) cell manufacturing facility is being built to support academic and private sector partners. A partnership with the new CellCAN Regenerative Medicine and Cell Therapy Knowledge Mobilization Network is working to harmonize the operations of this and existing facilities across Canada.
  • CCRM is collaborating with Japan-based 360ip and the Stem Cells Australia consortium in Melbourne to share intellectual property, increase the translation of stem cell research, and identify new opportunities for investment.
  • CCRM is the commercialization vehicle for the Ontario-China Stem Cell Partnership, which will see researchers from both countries collaborate in several areas of RM.
  • Hemostemix , a Canadian-Israeli company, is receiving CCRM support to advance a phase 2 clinical trial in Canada for patients with critical limb ischemia, a severe blockage in the arteries of the lower extremities.
  • CCRM and the UK’s Cell Therapy Catapult are collaborating to support multinational clinical trials, technology development, standardization and workshops.
  • CCRM, the Stem Cell Network NCE and the MaRS Innovation CECR work together to develop and commercialize stem cell-based technologies and find investors for start-up companies.
  • CCRM has conducted diligence on 200 technologies/cell therapies from Canada and internationally.
  • CCRM has launched funds with Pfizer and the McEwen Centre in Toronto to encourage innovation in industry and commercialization in academia.

Connect with CCRM

 

News
June 23, 2016
December 23, 2014
December 11, 2014
October 20, 2014
January 2, 2014
Features
Building Canada's Strengths: Regenerative Medicine
April 17, 2014
Canada is recognized as a global leader in stem cell and bioengineering science, with over 400 stem cell scientists working in 68 research centres within, or affiliated with, 25 Canadian universities. Given its rich history of research excellence in the field, this country is uniquely placed to be one of the earliest beneficiaries of stem cell advances. Read more
Building Canada's Strengths: Drug Discovery and Commercialization
April 17, 2014
Developing new drugs is a long, complex and expensive process. The NCE supports several models that are helping reduce the risk and accelerate the commercialization of medical innovations that will improve health-care delivery and patient care in Canada and abroad. Read more
Take it from the top – strong leadership means better results
November 14, 2012
The Board of Directors for an NCE network or centre often reads like the Who’s Who list of a particular sector, featuring top experts and prominent figures from industry and academia. Pulling together that room full of heavy hitters is an important part of the innovative approaches to governance and best practices adopted by NCE-funded organizations to achieve their goals. Read more
Videos
Watch Video
CCRM Sits Down With... Molly Shoichet, University of Toronto
May 1, 2014
Watch Video
Cell Culture with Bioreactors
March 31, 2014
Watch Video
CCRM Sits down with... Michael D. West, CEO of BioTime
November 29, 2013
Watch Video
CCRM Sits Down with... Stephen Minger
November 4, 2013